Clinical validation of the Cervista® HPV HR and 16/18 genotyping tests for use in women with ASC-US cytology

Gynecologic Oncology

Volumn 118, Issue 2, 2010, Pages 116-122

  Einstein, Mark H ^a   Martens, Mark G ^b   Garcia, Francisco A R ^c   Ferris, Daron G ^d   Mitchell, Amy L ^c   Day, Stephen P ^e   Olson, Marilyn C ^e  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b JERSEY SHORE UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF ARIZONA   (United States)

^d MEDICAL COLLEGE OF GEORGIA   (United States)

^e HOLOGIC INC   (United States)

Author keywords

ASC US; Colposcopy; Genotyping; High risk HPV; Triage

Indexed keywords

DNA;

ADULT; ARTICLE; CANCER RISK; CANCER SCREENING; CLINICAL STUDY; CLINICAL TRIAL; COLPOSCOPY; DIAGNOSTIC ACCURACY; DNA EXTRACTION; FEMALE; GENOTYPE; HEALTH CARE; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PAPANICOLAOU TEST; PATHOLOGY; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; SQUAMOUS CELL; STANDARD; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; UTERUS BIOPSY; VALIDATION PROCESS; VIRUS DETECTION;

ADOLESCENT; ADULT; CERVICAL INTRAEPITHELIAL NEOPLASIA; CERVIX UTERI; COLPOSCOPY; FEMALE; GENOTYPE; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; PAPILLOMAVIRUS INFECTIONS; PROSPECTIVE STUDIES; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS; YOUNG ADULT;

EID: 77954242029     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2010.04.013     Document Type: Article

References (29)

1. J.M. Walboomers, M.V. Jacobs, M.M. Manos, F.X. Bosch, J.A. Kummer, and K.V. Shah Human papillomavirus is a necessary cause of invasive cervical cancer worldwide J Pathol. 189 1 1999 Sep 12 19
2. World Health Organization and IARC IARC monographs on the evaluation of carcinogenic risks to humans: human papillomaviruses 2005 Who Press Geneva, Switzerland 90
3. C.J. Meijer, P.J. Snijders, and P.E. Castle Clinical utility of HPV genotyping Gynecol Oncol 103 1 2006 Oct 12 17
4. J.S. Smith, L. Lindsay, B. Hoots, J. Keys, S. Franceschi, and R. Winer Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update Inter J Can. 121 3 2007 Aug 1 621 632
5. C.M. Wheeler, W.C. Hunt, N.E. Joste, C.R. Key, W.G. Quint, and P.E. Castle Human papillomavirus genotype distributions: implications for vaccination and cancer screening in the United States J Natl Cancer Inst. 101 7 2009 475 487
6. D.D. Davey, M.H. Neal, D.C. Wilbur, T.J. Colgan, P.E. Styer, and D.R. Mody Bethesda 2001 implementation and reporting rates: 2003 practices of participants in the College of American Pathologists Interlaboratory Comparison Program in Cervicovaginal Cytology Arch Pathol Lab Med 128 11 2004 Nov 1224 1229
7. D. Saslow, C.D. Runowicz, D. Solomon, A.B. Moscicki, R.A. Smith, and H.J. Eyre American Cancer Society guideline for the early detection of cervical neoplasia and cancer CA Cancer J Clin 52 6 2002 Nov-Dec 342 362 (Pubitemid 35446606)
8. T.C. Wright Jr, M. Schiffman, D. Solomon, J.T. Cox, F. Garcia, and S. Goldie Interim guidance for the use of human papillomavirus DNA testing as an adjunct to cervical cytology for screening Obstet Gynecol 103 2 2004 Feb 304 309
9. D. Solomon, D. Davey, R. Kurman, A. Moriarty, D. O'Connor, and M. Prey The 2001 Bethesda System: terminology for reporting results of cervical cytology JAMA. 287 16 2002 Apr 24 2114 2119
10. hc2 HPV DNA test [package insert]. Gaithersburg, MD: Digene (now Qiagen); 2007.
11. M. Poljak, I.J. Marin, K. Seme, and A. Vince Hybrid Capture II HPV Test detects at least 15 human papillomavirus genotypes not included in its current high-risk probe cocktail J Clin Virol. 25 suppl 3 2002 Dec S89 S97
12. T.E. Schutzbank, C. Jarvis, N. Kahmann, K. Lopez, M. Weimer, and A. Yount Detection of high-risk papillomavirus DNA with commercial invader-technology- based analyte-specific reagents following automated extraction of DNA from cervical brushings in ThinPrep media J Clin Microbiol. 45 12 2007 Dec 4067 4069
13. P.E. Castle, D. Solomon, C.M. Wheeler, P.E. Gravitt, S. Wacholder, and M. Schiffman Human papillomavirus genotype specificity of hybrid capture 2 J Clin Microbiol. 46 8 2008 Aug 2595 2604
14. TM HPV HR test as determined by a multi-center study J Clin Virol. 45 S1 2009 S63 S72
15. T.C. Wright Jr, L.S. Massad, C.J. Dunton, M. Spitzer, E.J. Wilkinson, and D. Solomon 2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests Am J Obstet Gynecol 197 4 2007 Oct 346 355 (Pubitemid 47464164)
16. Cervista® HPV HR [package insert]. Madison, WI: Hologic, Inc; 2009 (P/N 15-3100).
17. GenfindTM DNA Extraction Kit [package insert]. Madison, WI: Hologic, Inc; 2009 (P/N 15-3110). Web site: http://www.fda.gov/MedicalDevices/ ProductsandMedicalProcedures/ DeviceApprovalsandClearances/Recently- ApprovedDevices/ucm134056.htm.
18. Cervista® HPV 16/18 [package insert]. Madison, WI: Hologic, Inc; 2009.
19. G.M. Clifford, R.K. Rana, S. Franceschi, J.S. Smith, G. Gough, and J.M. Pimenta Human papillomavirus genotype distribution in low-grade cervical lesions: comparison by geographic region and with cervical cancer Cancer Epidemiol Biomarkers Prev 14 5 2005 May 1157 1164
20. M.E. Sherman, M. Schiffman, and J.T. Cox Effects of age and human papilloma viral load on colposcopy triage: data from the randomized Atypical Squamous Cells of Undetermined Significance/Low-Grade Squamous Intraepithelial Lesion Triage Study (ALTS) J Natl Cancer Inst. 94 2 2002 Jan 16 102 107
21. D. Solomon, M. Schiffman, and R. Tarone Comparison of three management strategies for patients with atypical squamous cells of undetermined significance: baseline results from a randomized trial J Nat Can Inst. 93 4 2001 Feb 21 293 299 (Pubitemid 32219816)
22. M. Arbyn, F. Buntinx, M. Van Ranst, E. Paraskevaidis, P. Martin-Hirsch, and J. Dillner Virologic versus cytologic triage of women with equivocal Pap smears: a meta-analysis of the accuracy to detect high-grade intraepithelial neoplasia J Nat Can Inst. 96 4 2004 Feb 18 280 293 (Pubitemid 38256273)
23. S. Broder From the National Institutes of Health JAMA 267 14 1992 Apr 8 1892
24. M.H. Stoler, P.E. Castle, D. Solomon, and M. Schiffman The expanded use of HPV testing in gynecologic practice per ASCCP-guided management requires the use of well-validated assays Am J Clin Pathol 127 3 2007 Mar 335 337
25. L.R. Johnson, C.R. Starkey, J. Palmer, J. Taylor, S. Stout, and S. Holt A comparison of two methods to determine the presence of high-risk HPV cervical infections Am J Clin Pathol 130 3 2008 Sep 401 408
26. V. Bouvard, R. Baan, K. Straif, Y. Grosse, and B. Secretan El Ghissassi F, et al. A review of human carcinogens-Part B: biological agents Lancet Oncol. 10 4 2009 321 322
27. C.M. Wheeler, W.C. Hunt, M. Schiffman, and P.E. Castle Human papillomavirus genotypes and the cumulative 2-year risk of cervical precancer J Infect Dis. 194 9 2006 Nov 1 1291 1299
28. M.H. Mayrand, E. Duarte-Franco, I. Rodrigues, S.D. Walter, J. Hanley, and A. Ferenczy Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer N Eng J Med. 357 16 2007 Oct 18 1579 1588
29. ASCCP. ASCCP: HPV genotyping clinical update. Available at: http://www.asccp.org/pdfs/consensus/clinical-update-20090408.pdf. Accessed: October 1, 2009.